Literature DB >> 7519201

Urapidil permeates the intact blood-brain barrier.

G Castor1, U Schmidt.   

Abstract

OBJECTIVE: To determine the plasma and cerebrospinal fluid (CSF) levels of urapidil after i.v. administration and the effect on CSF serotonin and 5-hydroxyindoleacetic acid (5-HIAA) concentrations.
DESIGN: Open, single-dose study.
SETTING: Post-surgery following neurosurgical removal of the hypophysis (n = 5) or aneurysm clipping (n = 1). PATIENTS: 6 patients, aged 32-71 years, with intact blood-brain barrier (BBB); 1 patient was studied twice.
INTERVENTIONS: Single dose of 25 mg urapidil i.v. as prophylaxis of BP increase during extubation or as treatment of hypertensive episodes. MEASUREMENTS AND
RESULTS: Urapidil, serotonin and 5-HIAA were measured by HPLC in CSF during 8 h after urapidil administration. Urapidil was detected in CSF as soon as 5 min after injection in 3 patients. The concentration ratio of plasma/CSF after the distribution phase was about 5:1. No significant effect on serotonin and 5-HIAA in CSF was seen.
CONCLUSION: After administration of a therapeutic dose, urapidil permeates the BBB and may interact with central 5-HT1A-receptors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7519201     DOI: 10.1007/bf01708965

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  9 in total

1.  Experimental studies on the neurocardiovascular effects of urapidil.

Authors:  R A Gillis; K J Kellar; J A Quest; I J Namath; A Martino-Barrows; K Hill; P J Gatti; K Dretchen
Journal:  Drugs       Date:  1988       Impact factor: 9.546

2.  Cerebrospinal fluid amine metabolites. Relationships with behavioral measurements in depressed, manic, and healthy control subjects.

Authors:  D E Redmond; M M Katz; J W Maas; A Swann; R Casper; J M Davis
Journal:  Arch Gen Psychiatry       Date:  1986-10

3.  Determinations of 5-hydroxyindoleacetic acid and homovanillic acid in human CSF with monitoring of probenecid levels in CSF and plasma.

Authors:  B M Emanuelsson; E Widerlöv; H Walléus; L K Paalzow
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

4.  Cerebrospinal fluid 5-hydroxyindoleacetic acid as an index of central serotonergic processes.

Authors:  C M Banki; G Molnár
Journal:  Psychiatry Res       Date:  1981-08       Impact factor: 3.222

5.  Permeation of the blood-brain barrier by urapidil and its influence on intracranial pressure in man in the presence of compromised intracranial dynamics.

Authors:  C Anger; H van Aken; P Feldhaus; R Wüsten; H Konig; K H Krahling; P Lawin
Journal:  J Hypertens Suppl       Date:  1988-12

6.  Determination of urapidil and its metabolites in human serum and urine: comparison of liquid-liquid and fully automated liquid-solid extraction.

Authors:  K Zech; R Huber
Journal:  J Chromatogr       Date:  1986-02-26

7.  Urapidil and some analogues with hypotensive properties show high affinities for 5-hydroxytryptamine (5-HT) binding sites of the 5-HT1A subtype and for alpha 1-adrenoceptor binding sites.

Authors:  G Gross; G Hanft; N Kolassa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-12       Impact factor: 3.000

Review 8.  Evidence for the interaction of urapidil with 5-HT1A receptors in the brain leading to a decrease in blood pressure.

Authors:  N Kolassa; K D Beller; K H Sanders
Journal:  Am J Cardiol       Date:  1989-02-02       Impact factor: 2.778

9.  5-HIAA and HVA in CSF in patients with idiopathic pain disorders.

Authors:  B G Almay; J Häggendal; L von Knorring; L Oreland
Journal:  Biol Psychiatry       Date:  1987-04       Impact factor: 13.382

  9 in total
  1 in total

Review 1.  Urapidil. A reappraisal of its use in the management of hypertension.

Authors:  M Dooley; K L Goa
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.